Differentiated thyroid cancer is known to have a good prognosis and usually has a slow progression. A recent study questions the need for using the established radioiodine therapy for remnant ablation after total thyroidectomy. However, initial radioiodine therapy reduces the rate of relapse and is an excellent diagnostic tool that improves follow-up.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McLeod, D. S., Sawka, A. M. & Cooper, D. S. Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet 381, 1046–1057 (2013).
Nixon, I. J. et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid 23, 683–694 (2013).
American Thyroid Association guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009).
Pacini, F. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154, 787–803 (2006).
Wada, N. et al. Prognostic value of the sixth edition AJCC/UICC TNM classification for differentiated thyroid carcinoma with extrathyroid extension. J. Clin. Endocrinol. Metab. 92, 215–218 (2007).
Brassard, M. et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J. Clin. Endocrinol. Metab. 96, 1352–1359 (2011).
Durante, C. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892–2899 (2006).
Pagano, L. et al. Follow-up of differentiated thyroid carcinoma. Minerva Endocrinol. 29, 161–174 (2004).
Mazzaferri, E. L. & Jhiang, S. M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97, 418–428 (1994).
Cheng, W. et al. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. J. Clin. Endocrinol. Metab. 98, 1353–1360 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bockisch, A., Rosenbaum-Krumme, S. The effect of radioiodine therapy after total thyroidectomy. Nat Rev Endocrinol 9, 511–512 (2013). https://doi.org/10.1038/nrendo.2013.153
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2013.153
This article is cited by
-
Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative 124I-NaI-PET/CT in patients with papillary thyroid cancer
European Journal of Nuclear Medicine and Molecular Imaging (2016)
